Your browser is no longer supported. Please, upgrade your browser.
Settings
TGTX TG Therapeutics, Inc. daily Stock Chart
TGTX [NASD]
TG Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.59 Insider Own18.10% Shs Outstand59.00M Perf Week4.04%
Market Cap607.70M Forward P/E- EPS next Y-1.42 Insider Trans-0.23% Shs Float46.03M Perf Month-7.21%
Income-78.30M PEG- EPS next Q-0.36 Inst Own50.60% Short Float22.69% Perf Quarter145.24%
Sales0.20M P/S3038.50 EPS this Y-15.70% Inst Trans13.70% Short Ratio4.82 Perf Half Y74.58%
Book/sh0.73 P/B14.11 EPS next Y-1.40% ROA-96.20% Target Price24.00 Perf Year1.63%
Cash/sh0.76 P/C13.53 EPS next 5Y- ROE-120.00% 52W Range4.10 - 15.05 Perf YTD121.51%
Dividend- P/FCF- EPS past 5Y40.90% ROI- 52W High-31.56% Beta1.04
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low151.22% ATR0.76
Employees64 Current Ratio3.00 Sales Q/Q0.00% Oper. Margin- RSI (14)52.36 Volatility6.00% 6.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-31.40% Profit Margin- Rel Volume0.52 Prev Close10.45
ShortableYes LT Debt/Eq0.00 EarningsMar 10 BMO Payout- Avg Volume2.17M Price10.30
Recom1.50 SMA20-4.41% SMA5011.50% SMA20052.71% Volume1,120,484 Change-1.44%
Mar-06-17Reiterated FBR & Co. Outperform $24 → $26
Oct-06-16Resumed Brean Capital Buy $28
May-27-16Initiated SunTrust Buy $18
Dec-01-15Initiated FBR Capital Outperform $29
Sep-09-15Initiated Raymond James Strong Buy
Aug-12-15Resumed H.C. Wainwright Buy $22
Jun-19-15Reiterated Brean Capital Buy $22 → $28
Dec-11-14Reiterated ROTH Capital Buy $25 → $33
Dec-10-14Reiterated ROTH Capital Buy $25 → $33
Oct-27-14Initiated H.C. Wainwright Buy $17
Sep-25-14Reiterated Brean Capital Buy $19 → $22
Jul-22-14Reiterated Brean Capital Buy $13 → $19
Jul-02-14Reiterated MLV & Co Buy $10 → $16
Apr-04-14Initiated Brean Capital Buy $13
Mar-07-14Reiterated MLV & Co Buy $9 → $11
Nov-25-13Reiterated Ladenburg Thalmann Buy $8 → $12
Nov-06-13Initiated MLV & Co Buy $9
Apr-21-17 10:57AM  Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics Benzinga
Apr-20-17 06:22PM  If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss TheStreet.com
02:00PM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
Apr-18-17 07:30AM  FDA Drug Approvals on the Rise in 2017: Today's Research Reports on Sarepta Therapeutics and TG Therapeutics Accesswire
Apr-07-17 08:30AM  Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock? Zacks
Apr-04-17 01:22PM  TG Therapeutics stock rises 2% on preclinical data for cancer drug MarketWatch
01:22PM  TG Therapeutics stock rises 2% on preclinical data for cancer drug
01:00PM  TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Companys Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting GlobeNewswire
01:00PM  TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Companys Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting
Apr-03-17 04:23PM  3 Top Biotech Stocks to Buy in April Motley Fool -5.15%
04:23PM  3 Top Biotech Stocks to Buy in April at Motley Fool
Mar-30-17 10:33AM  5 Top Performing Stocks of the Best ETF of Q1 Zacks
10:33AM  5 Top Performing Stocks of the Best ETF of Q1
Mar-27-17 04:07PM  ETFs with exposure to TG Therapeutics, Inc. : March 27, 2017 Capital Cube
04:07PM  ETFs with exposure to TG Therapeutics, Inc. : March 27, 2017
Mar-22-17 01:04PM  TG THERAPEUTICS, INC. Financials -5.53%
08:32AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017 Capital Cube
08:32AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017
Mar-20-17 07:30AM  TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-19-17 01:51PM  Don't Let Offerings Blindside Your Thesis
Mar-17-17 07:30AM  TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference GlobeNewswire
Mar-16-17 09:30AM  TG Therapeutics and ImmunoGen are Models of Institutional Investor Attention Accesswire
06:11AM  TG THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Mar-13-17 07:30AM  TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference GlobeNewswire +7.02%
Mar-10-17 07:54AM  TG Therapeutics reports 4Q loss
07:37AM  Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps
07:34AM  TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events
07:30AM  TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update GlobeNewswire
07:07AM  Q4 2016 TG Therapeutics Inc Earnings Release - After Market Close
Mar-09-17 05:06PM  TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme +16.26%
04:30PM  TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2016 Financial Results and Business Update GlobeNewswire
09:19AM  TG Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock GlobeNewswire
Mar-08-17 04:01PM  TG Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire -6.88%
Mar-07-17 07:20PM  Cramer's lightning round: Best-in-show pipeline stocks at CNBC +6.86%
01:55PM  Harry Boxers six biotechnology stocks to watch at MarketWatch
11:48AM  Heres Whats Next For TG Therapeutics Inc (TGTX) at Insider Monkey
10:25AM  DEADLINE TODAY FOR TGTX INVESTORS: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:03AM  DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against TG Therapeutics, Inc. and Announces a Lead Plaintiff Deadline of March 7, 2017 - TGTX PR Newswire
Mar-06-17 05:35PM  Tyson and Deutsche Bank slide; Southwestern Energy jumps +90.65%
04:35PM  Why Range Resources, Central European Media Enterprises, and TG Therapeutics Jumped Today at Motley Fool
03:53PM  TG Therapeutics Surges 85% on Results From Study
01:45PM  Mondays Top Health Care Stocks Screaming Higher
01:36PM  How to Trade Monday's Most Active Stocks - Snap, GM, TG Therapeutics and More
01:15PM  Why TG Therapeutics Stock Exploded Higher Today at Motley Fool
11:27AM  IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire
10:35AM  TG Therapeutics' leukemia drug clears key study, shares pop
07:39AM  TG Therapeutics' stock shoots up toward 5-month high after positive test results at MarketWatch
07:22AM  TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events
07:14AM  TG Therapeutics' leukemia drug clears hurdle in key study
07:00AM  TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL) GlobeNewswire
Mar-03-17 08:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - TGTX Accesswire
11:34AM  TGTX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TG Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 GlobeNewswire
07:30AM  TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting GlobeNewswire
Mar-02-17 02:06PM  TGTX Investors Deadline Alert: GPM Reminds Investors of the March 7 Deadline in the Class Action Lawsuit Against TG Therapeutics, Inc. Business Wire
Feb-28-17 02:27PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
09:59AM  INVESTOR ALERT: Monteverde & Associates PC Reminds TG Therapeutics, Inc. Shareholders To Contact The Firm Before March 7, 2017 Class Action Deadline - TGTX Accesswire
Feb-27-17 03:41PM  IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire
02:19PM  DEADLINE ALERT: Brower Piven Reminds Investors Of The March 7, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In TG Therapeutics, Inc. To Contact The Firm Business Wire
12:43PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
12:04PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against TG Therapeutics, Inc. and Announces a Lead Plaintiff Deadline of March 7, 2017 TGTX GlobeNewswire
Feb-25-17 01:15PM  IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire
08:17AM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in TG Therapeutics, Inc. to Contact the Firm Before Imminent Lead Plaintiff Deadline Accesswire
Feb-24-17 09:21PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire +5.36%
08:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - TGTX Accesswire
10:30AM  The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Rentech, Inc. Investors and Encourages Investors to Contact the Firm Business Wire
Feb-23-17 09:39AM  [2/23] This Weeks Earnings Revisions Movers +8.74%
Feb-21-17 10:57AM  IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire
10:29AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against TG Therapeutics, Inc. and Announces a Lead Plaintiff Deadline of March 7, 2017 Business Wire
07:30AM  TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1/2 Trial of TG-1101 (ublituximab) Monotherapy in the British Journal of Haematology GlobeNewswire
Feb-17-17 08:31PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
08:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - TGTX Accesswire
Feb-16-17 07:09PM  IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire
05:04PM  URGENT: Monteverde & Associates PC Encourages TG Therapeutics, Inc. Shareholders with Losses To Contact The Firm Immediately - TGTX PR Newswire
Feb-15-17 11:29AM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:31AM  TGTX SHAREHOLDER REMINDER: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TG Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 Business Wire
Feb-14-17 06:45PM  Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. (TGTX) and Encourages Investors with Losses to Contact the Firm Business Wire
Feb-11-17 07:27AM  IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire
Feb-10-17 08:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline TGTX GlobeNewswire
11:49AM  IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
11:10AM  TGTX UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TG Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 PR Newswire
Feb-09-17 07:30AM  TG Therapeutics, Inc. to Present at the 2017 BIO CEO & Investor Conference GlobeNewswire +5.26%
Feb-06-17 05:51PM  IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire
05:26PM  Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. (TGTX) and Encourages Investors to Contact the Firm Business Wire
04:00PM  Safirstein Metcalf LLP Announces That A Class Action Lawsuit Has Been Filed Against TG Therapeutics - TGTX GlobeNewswire
11:45AM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
11:10AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against TG Therapeutics, Inc. and Announces a Lead Plaintiff Deadline of March 7, 2017 Business Wire
Feb-03-17 08:30PM  IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire +7.61%
07:02PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - TGTX PR Newswire
02:16PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
01:05PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In TG Therapeutics, Inc. (TGTX) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit GlobeNewswire
01:00PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire
10:30AM  INVESTOR ALERT: Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of TG Therapeutics, Inc. Investors and Encourages Investors to Contact the Firm Business Wire
Feb-01-17 11:08AM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:06AM  TGTX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TG Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 Business Wire
Jan-30-17 07:07PM  IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire
02:56PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In TG Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline PR Newswire
Jan-27-17 01:28PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
11:57AM  TGTX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving TG Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 GlobeNewswire
Jan-25-17 08:15AM  Blog Coverage FDA Approved Orphan Drug Designation for TG Therapeutics' Combination of TG-1101 and TG-1202 Accesswire +6.45%
Jan-24-17 02:29PM  IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm Accesswire +9.41%
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KENNEDY WILLIAM JAMESDirectorApr 11Sale10.278,54887,78870,401Apr 12 05:44 PM
Charney Laurence NDirectorApr 04Sale11.177,00078,19088,949Apr 04 05:57 PM
Power Sean ACFO, Secretary and TreasurerJan 04Sale4.558,81640,113507,440Jan 04 05:28 PM
Power Sean ACFO, Secretary and TreasurerJul 05Sale5.9950,426302,052416,256Jul 08 08:06 PM